Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | ARI0002h |
| Trade Name | |
| Synonyms | ARI-0002h|ARI 0002h|cesnicabtagene autoleucel|ARI2h |
| Drug Descriptions |
ARI0002h (cesnicabtagene autoleucel) are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting the B-cell maturation antigen (BCMA) and containing TNFRSF9 (4-1BB) costimulatory and CD3zeta activation domains, which may induce cytotoxicity against tumor cells and inhibit tumor growth (PMID: 31919085, PMID: 37414060). |
| DrugClasses | TNFRSF17 Immune Cell Therapy 27 |
| CAS Registry Number | NA |
| NCIT ID | C176769 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| ARI0002h | ARI0002h | 0 | 1 |